A New York-based pharmaceutical company, Pfizer has successfully produced a vaccine that is reported to have passed the early stages of safety and effectiveness tests.
The result of the vaccines after being injected into healthy adults shows that it produces a better immune reaction compared to cured COVID patients according to nature.
According to medicalxpress, the new trial involved 45 healthy adults with ages ranging from 18 to 55. Among the participants, half were randomly selected to get the vaccine at a low, medium, or high dose, while the other half got a “dummy” placebo shot.
Although the results are promising, researchers are still focusing on the third phase of testing. During this phase, the vaccine is tested in a much larger population where the safety, strength, and duration of any protective effect is going to put to the test.
It is also reported by the journal that the vaccine was “generally well-tolerated,” although some recipients did experience a few transitory side effects such as soreness at the injection site, fatigue, headache, fever, and sleep woes. However, those tended to clear up within a week of vaccination.
Dr Judith Absalon, of drug giant Pfizer Inc, said that according to her team, BNT162b1 which is the name of the vaccine is “based on a bit of genetic code known as messenger RNA, which helps kick-start the body’s immune response when it encounters the new coronavirus.” as reported by medicalxpress.
With the progress of finding a vaccine for COVID, surely it is a sign of good news to come. What are your thoughts about this? Let us know in the comments!
Also read: Could Russia’s Plan To Register World’s First Covid-19 Vaccine Soon, Be Too Good To Be True?
